This page shows anti-doping rule violation data we have registered for Erythropoietin.
Erythropoietin ranks #6 globally among prohibited substances, with 598 registered cases (4.1% of all violations) among all sports tracked by the Anti-Doping Database, which contains 14,670 verified cases. Russia leads with 69 cases, while Cycling is the most affected sport (251 cases).
Cycling has the most recorded cases of Erythropoietin violations globally, with 251 registered cases — 0% of all 598 verified cases.
Russia leads in Erythropoietin violations globally, with 69 registered cases — 11.5% of all 598 verified cases.
Erythropoietin ranks #6 of 358 prohibited substances in the Anti-Doping Database.
This ranking covers only prohibited substances with verified case records in the Anti-Doping Database. Procedural violations (whereabouts failures, refusals to test, etc.) are excluded.
The average suspension for Erythropoietin violations is 39.4 months, longer than the global average of 30.1 months.
Erythropoietin (EPO) is a naturally occurring hormone that stimulates red blood cell production. Synthetic EPO became available as a pharmaceutical drug in the late 1980s, primarily for medical use in patients with anemia and kidney disease. Related drugs, such as Darbepoetin Alfa, have since been developed.
In sports, EPO enhances oxygen-carrying capacity by increasing red blood cell count, providing significant advantages in endurance events such as cycling, long-distance running, and cross-country skiing. The increased oxygen delivery to muscles can dramatically improve stamina and performance.
Artificially elevated red blood cell levels thicken the blood, significantly increasing the risk of serious cardiovascular complications including blood clots, heart attack, stroke, hypertension, seizures, and congestive heart failure. The risks are particularly acute during sleep when heart rate naturally decreases, as the thickened blood becomes more difficult to circulate at lower heart rates.
EPO was added to the IOC prohibited list in 1989, initially categorized under peptide hormones and analogues. However, testing methods were not immediately available, allowing widespread use in the early 1990s.
On August 1, 2000, the IOC Medical Commission approved two detection methods for EPO based on isoelectric focusing and double immunoblotting, which distinguish between natural and synthetic EPO in urine samples. Modern detection methods and hematocrit monitoring have made EPO use more detectable, though related substances and microdosing practices continue to challenge anti-doping authorities.
Belgian cycling champion Eddy Planckaert later confessed to experimenting with EPO in 1991, his final professional year, stating that many riders were using the substance during that period. Several Dutch and Belgian cyclists died suddenly in the late 1980s and early 1990s, sparking widespread concern about EPO's dangers.
However, academic research has questioned whether EPO was the cause of these deaths. A 2011 study by sports historian Bernat López examined claims that 18 Dutch and Belgian cyclists died from EPO use between 1987-1990 and found the claim lacked empirical evidence. López noted that reported numbers varied wildly across sources (from 6 to 40 deaths) and that most sudden deaths in young athletes are attributed to underlying cardiac conditions rather than drug use. The study concluded that the "18 deaths" narrative functioned more as anti-doping propaganda than historical fact.
If you use this data, please credit The Anti-Doping Database
Used by journalists, sport lawyers, NADOs and researchers worldwide for proactive strategy — not just post-case research.
As a subscriber you get instant access to verified, structured anti-doping case data — from hours of research to seconds:
The Anti-Doping Database currently contains 14,670 verified anti-doping rule violations across all sports and all countries, and is updated regularly.